LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those of the approved IPF treatment Ofev […] The post LTI-03 reduces inflammation, scarring in IPF lung samples: Study appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the clinical trial (NCT06331624). The company recently […] The post Experimental oral therapy GRI-0621 may stabilize lung function in IPF appeared first on Pulmonary Fibrosis News.| Pulmonary Fibrosis News – The Web's Daily Resource for PF News
There are more immune NK T-cells in the lungs of people with idiopathic pulmonary fibrosis than in healthy people, research shows| Pulmonary Fibrosis News
The inhaled NXP002 achieves significant levels in the lungs and lowers the production of scarring-promoting molecules, a study shows.| Pulmonary Fibrosis News
Nuformix received a notice of allowance from the U.S. Patent Office, and awaits a patent for NXP002, an inhaled form of tranilast for IPF.| Pulmonary Fibrosis News
Inconsistent results of NXP002, a new formulation of tranilast, delayed completion of the package needed for potential clinical trials.| Pulmonary Fibrosis News
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Taladegib has been granted orphan drug designation in the U.S. and the European Union as a treatment for idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
In CORAL, 165 IPF patients were given one of three doses of nalbuphine ER to test its ability to reduce cough frequency after six weeks.| Pulmonary Fibrosis News
